(Reuters) -The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to ...

children and adolescents, as well as pregnant and immunocompromised people, where the use of the vaccine outweighs its risks. Children are particularly vulnerable to mpox because their immune ...

The World Health Organisation on Tuesday approved an mpox vaccine from Japanese pharma company KM Biologics for emergency use, the second one to get the agency's seal of approval. The WHO said it ...

Bavarian Nordic’s Mpox vaccine met with the World Health Organization's approval on Monday for use among adolescents aged between 12-17. This age bracket is considered to be highly vulnerable to ...

The World Health Organization on Tuesday approved an mpox vaccine from Japanese pharma company KM Biologics for emergency use, the second one to get the agency's seal of approval. The WHO said it ...

The WHO said in a statement that it gave the Jynneos vaccine prequalification for adolescents on Oct. 8. The WHO declared mpox a global public health emergency for the second time in two years in ...

The World Health Organization said on Monday, October 14 that it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to ...